Non-Fiction Books:

γδT Cell Cancer Immunotherapy

Evidence-Based Perspectives for Clinical Translation
Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!
  • γδT Cell Cancer Immunotherapy on Hardback
  • γδT Cell Cancer Immunotherapy on Hardback
$429.00
Releases

Pre-order to reserve stock from our first shipment. Your credit card will not be charged until your order is ready to ship.

Available for pre-order now
Free Delivery with Primate
Join Now

Free 14 day free trial, cancel anytime.

Buy Now, Pay Later with:

4 payments of $107.25 with Afterpay Learn more

6 weekly interest-free payments of $71.50 with Laybuy Learn more

Pre-order Price Guarantee

If you pre-order an item and the price drops before the release date, you'll pay the lowest price. This happens automatically when you pre-order and pay by credit card or pickup.

If paying by PayPal, Afterpay, Laybuy, Zip, Klarna, POLi, Online EFTPOS or internet banking, and the price drops after you have paid, you can ask for the difference to be refunded.

If Mighty Ape's price changes before release, you'll pay the lowest price.

Availability

This product will be released on

Delivering to:

It should arrive:

  • 6-13 September using International Courier

Description

?d T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation discusses the current pre-clinical and clinical ?d T cell landscape. The book not only focuses on the promises of what’s to come, but also on the challenges faced by the field. Particular attention is given to summarizing recent advances on what is known about relevant areas of ?d T cell biology on summarizing the ‘big picture’ clinical situation, an up-to-date systematic clinical trial review covering autologous, allogeneic, engineered and non-engineered therapies, and perspectives on the types of cutting-edge gene-engineering that may be required to enhance the effect-size and durability of therapeutic efficacy. Content provides updated and comprehensive insights into the current state of ?d T cell immunotherapy, including discussions on the promise as well as challenges of the field that is of interest to existing translational ?d T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?d T cell immunotherapy in the clinic or are wishing to familiarize themselves with non-canonical lymphocyte immunotherapy.

Author Biography:

Dr. Barisa is currently a Senior Fellow at University College London (UCL), specialising in experimental paediatric oncology, with a particular emphasis on allogeneic, gene-engineered ?dT cell immunotherapy for a range of solid tumour indications. In this capacity she works with two separate groups at UCL’s Zayed Centre of Great Ormond St Hospital, London UK: the Experimental Paediatric Oncology Research Group and the Allogeneic Immunotherapy Research Group. Awarded this year, she is co-investigator on a UCL Technology Fund-supported £2.5million grant to advance late-stage pre-clinical development of a gene-engineered ?dT cell immunotherapy pipeline, among others. She has previously worked on a range of academic and commercial ?dT cell therapy product development pipelines that have resulted in numerous patent applications, covering ?dT cell expansion for clinical use, their transduction with novel lentiviral strategies and new types of efficacy constructs to boost killing of tumour targets.
Release date NZ
September 1st, 2024
Audience
  • Professional & Vocational
Contributor
  • Edited by Marta Barisa
Pages
286
ISBN-13
9780443217661
Product ID
36864254

Customer previews

Nobody has previewed this product yet. You could be the first!

Write a Preview

Help & options

Filed under...